Blackstone and TPG Complete $18.3B Acquisition of Hologic
Investment firms TPG and Blackstone have finalized their acquisition of medical-technology company Hologic Inc. for up to $18.3 billion. Concurrently, José Almeida has been appointed as the new CEO of Hologic, succeeding Stephen MacMillan. The deal includes a cash payment of $76 per share to Hologic stockholders, with potential additional payments up to $3 per share based on future revenue goals.
Blackstone, TPG Complete $17.2B Acquisition of Hologic
Private equity firms Blackstone and TPG Global, along with Abu Dhabi Investment Authority and GIC Private Limited, have completed their $17.2 billion acquisition of medical diagnostics firm Hologic, Inc. This deal, initially announced in October 2025, underscores a growing investor interest in the medical diagnostics industry and the medical technology sector. Hologic will maintain its Marlborough, Massachusetts headquarters and brand, with a focus on expanding its diagnostic testing and women's health product offerings.
Former Baxter chief takes helm at Marlborough medical device maker
José Almeida, former CEO of Baxter International and Covidien, has been named the new chief executive of Hologic Inc., a Marlborough-based medical device maker. This appointment follows the company's buyout by two private equity firms, prompting the resignation of nine board members as Hologic transitioned to private ownership. Despite its focus on women's health, Hologic has not previously had a female chief executive.
Blackstone, TPG Complete $17.2B Acquisition of Hologic
Blackstone Inc., TPG Global, LLC, along with the Abu Dhabi Investment Authority and GIC Private Limited, completed their $17.2 billion acquisition of medical diagnostics firm Hologic, Inc. The deal, which first received shareholder and regulatory approvals, including from China and the European Union, is expected to expand the healthcare portfolios of Blackstone and TPG and signals continued private equity interest in the medical technology sector. Hologic will maintain its headquarters in Marlborough, Massachusetts, and continue operating under its existing brand and leadership with a focus on expanding its diagnostic testing and women's health product offerings.
[POS AM] HOLOGIC INC SEC Filing
Hologic, Inc. (HOLX) has filed a Post-Effective Amendment to its S-3 Registration Statements, indicating the deregistration of its securities following its acquisition. On April 7, 2026, Hologic merged with Hopper Merger Sub Inc., a wholly-owned subsidiary of Hopper Parent Inc., terminating the offering and sale of Hologic's securities under the previous registration statements. The filing confirms the removal of all unsold securities from registration and the termination of the effectiveness of the registration statements.
Hologic goes private in $79 per share buyout by Blackstone, TPG
Hologic Inc. has transitioned to private ownership in a $79 per share buyout by funds managed by Blackstone and TPG, with minority investments from Abu Dhabi Investment Authority and GIC. Joe Almeida has been appointed CEO, replacing Stephen MacMillan. Stockholders received $76 per share in cash plus a non-tradable contingent value right of up to $3 per share, dependent on future Breast Health business revenue goals.
The funds managed by Blackstone Inc. (NYSE:BX), TPG Global, LLC along with Abu Dhabi Investment Authority and GIC Private Limited completed the acquisition of Hologic, Inc..
Funds managed by Blackstone Inc. (NYSE:BX), TPG Global, LLC, Abu Dhabi Investment Authority, and GIC Private Limited have completed the acquisition of Hologic, Inc. (NasdaqGS:HOLX) for $17.2 billion. Hologic's common stock ceased trading and was delisted from Nasdaq, and José E. Almeida has been appointed as the new CEO.
Casey’s joining S&P 500 on Thursday
Casey’s General Stores Inc. is set to join the S&P 500 on Thursday, replacing Hologic Inc., which is being acquired. Casey’s shares rose after the announcement and the company recently reported a significant increase in net income for its third quarter, up 49.3% to $130.1 million. The convenience store chain is also the third-largest c-store retailer and fifth-largest pizza chain in the U.S., with plans for continued growth.
Casey’s joining S&P 500 on Thursday
Convenience store chain Casey's General Stores Inc. will replace Hologic Inc. in the S&P 500 before trading opens on Thursday. This move follows Casey's strong financial performance, with net income up 49.3% in the third quarter and its stock hitting a 52-week high. The changes are part of the index's quarterly rebalance, often triggering stock buying and selling by funds.
Hologic goes private in $79 per share buyout by Blackstone, TPG
Hologic Inc. has completed its acquisition by Blackstone and TPG, transitioning the women's health company to private ownership in a deal valued at up to $79 per share. Joe Almeida has been appointed CEO, replacing Stephen MacMillan. Stockholders will receive $76 per share in cash plus a contingent value right for up to $3 per share based on future revenue goals, and Hologic's common stock has ceased trading on Nasdaq.
Blackstone and TPG Complete Acquisition of Hologic
Blackstone and TPG have completed their acquisition of Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, taking the company private in a transaction valued at up to $79 per share. José (Joe) E. Almeida, former Chairman, President, and CEO of Baxter International Inc., has been appointed as the new Chief Executive Officer of Hologic. The acquisition also includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC.
Hologic Announced Transfer or Voluntary Withdrawal of Listing
Hologic (HOLX) has announced its intention to suspend trading and delist its common stock from Nasdaq following a merger. The company plans to file Form 25 for delisting and deregistration, and Form 15 to terminate registration and suspend its Exchange Act reporting obligations. This action was prompted by the completion of its merger.
Blackstone and TPG Complete Acquisition of Hologic
Blackstone and TPG have finalized their acquisition of Hologic, a global leader in women's health, in a deal valued at up to $79 per share, taking the company private. Concurrently, José (Joe) E. Almeida, former Chairman, President, and CEO of Baxter International Inc., has been appointed as Hologic's new Chief Executive Officer. The acquisition includes significant minority investments from ADIA and GIC, and Hologic stockholders received cash plus a contingent value right.
Blackstone and TPG Complete Acquisition of Hologic
Blackstone and TPG have finalized their acquisition of Hologic, a global leader in women’s health, for up to $79 per share, taking the company private. Joe Almeida has been appointed as the new Chief Executive Officer, effective immediately. The transaction, which includes significant minority investments from ADIA and GIC, aims to accelerate Hologic's innovation and growth in medical technologies.
Hologic (NASDAQ: HOLX) notifies Nasdaq of listing withdrawal
Hologic Inc. (NASDAQ: HOLX) has filed a Form 25 to notify the Nasdaq Stock Market LLC of the removal and withdrawal of its Common Stock from listing and registration. This action complies with 17 CFR 240.12d2-2 rules. The notification was executed by Nasdaq and signed by Tara Petta, AVP.
Blackstone, TPG take Hologic (NASDAQ: HOLX) private in $17.3B deal
Hologic, Inc. has been acquired by funds managed by Blackstone and TPG in a cash deal valued at approximately $17.3 billion, effectively taking the company private. Shareholders received $76.00 per share in cash plus one contingent value right (CVR) that could pay up to an additional $3.00 per share based on future Breast Health revenue milestones. In conjunction with this acquisition, José (Joe) E. Almeida has been appointed as the new Chief Executive Officer, succeeding Stephen MacMillan, and Hologic's common stock will be delisted from Nasdaq.
Hologic Closes $76-Per-Share Sale With CVR; Ends Credit Facility and Plans $1.35B Note Redemptions
Hologic has completed its merger with Hopper Parent, distributing $76.00 per share in cash and one contingent value right (CVR) per share to its shareholders, contingent on future revenue milestones. Concurrently, the company terminated its 2017 credit agreement after repaying all outstanding borrowings and initiated the redemption of $1.35 billion in senior notes due 2028 and 2029. These actions are aimed at simplifying Hologic's capital structure and linking potential additional shareholder consideration to post-merger performance.
Casey’s General Stores (CASY) Stock Surges 4% on S&P 500 Entry News
Casey’s General Stores (CASY) stock saw a 4% surge in after-hours trading after the announcement that it will join the S&P 500 on April 9. This move replaces Hologic (HOLX), which is being taken private by Blackstone and TPG. The inclusion is expected to drive institutional purchasing, given CASY's consistent positive earnings and strong fundamentals.
Casey's General Stores Added to S&P 500: Key Information for Investors
Casey's General Stores (CASY) is set to join the S&P 500 index on April 9, 2026, replacing Hologic (HOLX). While this inclusion typically boosts stock prices due to passive fund adjustments, analysts caution that Casey's already high valuation and operational challenges could limit long-term gains. Investors are advised to consider the company's ability to execute growth plans and the broader market environment, as the S&P 500 itself has not yet shown clear signs of a sustained recovery.
Casey’s General Stores Joining S&P 500 This Week
Casey's General Stores (CASY) is set to join the S&P 500 index, replacing Hologic Inc. (HOLX). This change, announced by S&P Dow Jones Indices, will take effect before trading opens on Thursday.
Blackstone (BX) and TPG Global Partner to Acquire Hologic
Blackstone (BX) and TPG Global are partnering to acquire Hologic, a strategic move reinforcing Blackstone's expansion in the healthcare sector. Despite recent stock price declines, Blackstone, the world's largest alternative-asset manager with $1.275 trillion in assets under management, maintains strong financial health marked by robust revenue growth and profitability. The acquisition highlights Blackstone's growth ambitions, though investors should consider its moderate leverage and higher market volatility.
S&P Dow Jones Indices says Casey's General Stores Inc. will replace Hologic Inc. in the S&P 500 effective prior to the market open on April 9
S&P Dow Jones Indices announced that Casey's General Stores Inc. will be added to the S&P 500 index, replacing Hologic Inc. This change will become effective before the market opens on April 9. The report was published on Reuters and MarketScreener.
S&P Dow Jones Indices Says Casey's General Stores Inc. Will Replace Hologic Inc. In The S&P 500 Effective Prior To The Market Open On April 9
S&P Dow Jones Indices has announced that Casey's General Stores Inc. (CASY) will replace Hologic Inc. (HOLX) in the S&P 500 index. This change will be effective prior to the market open on April 9. The article provides key information regarding the upcoming S&P 500 component change.
Hologic Inc stock hits 52-week high at $76.01 By Investing.com
Hologic Inc. stock reached a new 52-week high of $76.01, reflecting strong investor confidence and a 24.3% return over the past year. Despite recent fiscal first-quarter earnings missing analyst expectations, the company is undergoing significant corporate developments, including an acquisition by Blackstone and TPG, and FDA approval for its Aptima HPV Assay, signaling a period of strategic change and growth.
Encompass Health Corp Stock (EHC) Moved Up by 7.51% on Apr 6: What Signal Does It Send?
Encompass Health Corp (EHC) saw its stock rise by 7.51% on April 6, driven by a proposed increase in payment rates for rehabilitation hospitals by CMS and positive "Overweight" ratings from analysts like KeyBanc and Barclays. This upward movement occurred despite a recent securities fraud investigation, suggesting the market prioritized the favorable regulatory and analyst news. The company's strong Q4 2025 results also provided a positive financial foundation.
Hologic CEO Steve MacMillan to retire after go-private deal
Hologic CEO Steve MacMillan will retire following the company's acquisition by Blackstone and TPG for $18.3 billion. The deal is set to close on Tuesday after receiving all necessary regulatory approvals. MacMillan led Hologic for 13 years, significantly increasing revenue and share price, and will be succeeded by a new CEO named upon the acquisition's completion.
Hologic (HOLX) CEO Announces Retirement Amid Upcoming Transaction
Hologic (HOLX) CEO Steve MacMillan is retiring following the completion of a go-private transaction with Blackstone and TPG, which is expected to finalize around April 7, 2026. The company, specializing in women's healthcare diagnostics and medical devices, shows strong profitability despite declining revenue growth. Its financial health appears robust, with high institutional ownership and a neutral market sentiment.
Hologic Inc stock hits 52-week high at $76.01 By Investing.com
Hologic Inc. stock reached a new 52-week high of $76.01, demonstrating strong investor confidence in the medical technology company with a 24.3% return over the past year. This comes despite recent Q1 earnings missing analyst expectations, while the company also prepares for a CEO transition and celebrates FDA approval for its Aptima HPV Assay. InvestingPro analysis indicates the stock is fairly valued and has a "GREAT" financial health rating.
Hologic CEO Steve MacMillan to Retire After Private Equity Deal
Hologic CEO Steve MacMillan has announced his retirement following the impending closure of the $18.3 billion go-private transaction with Blackstone and TPG. During his 12-plus years, Hologic's revenue grew 65% and its share price increased 241%. The transaction is expected to close on or about April 7, 2026, with a new CEO to be announced afterward.
Hologic Inc stock hits 52-week high at $76.01
Hologic Inc.'s stock reached a new 52-week high of $76.01, indicating strong investor confidence and a 24.3% return over the past year. Despite slightly missing Q1 earnings estimates, the company is undergoing a CEO transition and recently gained FDA approval for its Aptima HPV Assay for primary screening, signaling ongoing strategic developments. InvestingPro analysis suggests the stock is fairly valued with a "GREAT" financial health score.
Hologic CEO Steve MacMillan To Retire
Hologic, Inc. announced that CEO Steve MacMillan will retire following the company's go-private transaction with Blackstone and TPG, expected to close around April 7, 2026. MacMillan's 12-plus year tenure saw significant growth in revenue, earnings per share, and stock price, along with the company's response to the COVID pandemic. The board and MacMillan expressed gratitude for his leadership, and a new CEO is expected to be announced upon the transaction's close.
Hologic's Stephen P. MacMillan to Retire as CEO and Chairman upon Blackstone/TPG Acquisition Close
Stephen P. MacMillan, the President, CEO, and Chairman of Hologic (HOLX), will retire from his positions immediately following the closing of the company's acquisition by affiliates of funds managed by Blackstone and TPG. This decision was informed to the Board and is effective upon the merger's completion. The information was disclosed in an SEC filing (8-K) on April 6, 2026.
Hologic (NASDAQ: HOLX) CEO exit tied to Blackstone, TPG buyout
Hologic, Inc. announced that CEO Steve MacMillan will retire immediately upon the closing of its go-private merger with affiliates of Blackstone and TPG, which is expected around April 7, 2026. All necessary regulatory approvals have been secured for the transaction. MacMillan's 12-year tenure saw significant growth in revenue, EPS, and share price, and his successor is anticipated to be announced upon the merger's completion.
Hologic's CEO will retire as Blackstone-TPG buyout nears close
Hologic, Inc. announced that its long-time Chairman, President, and CEO, Steve MacMillan, will retire upon the closing of its go-private transaction with Blackstone and TPG. The transaction is expected to close around April 7, 2026, after receiving all necessary regulatory approvals. MacMillan led Hologic for over 12 years, during which the company saw significant growth in revenue, non-GAAP earnings per share, share price, and workforce.
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript
VolitionRx Limited (AMEX:VNRX) reported strong Q4 and full-year 2025 results, with 40% revenue growth driven by its Nu.Q Discover platform and initial sales of Nu.Q NETs products. The company highlighted significant progress in commercializing its Nu.Q platform for human diagnostics, including partnerships with Werfen and Hologic, and critical advancements in feline cancer detection and a novel Capture-Seq technology for pure circulating tumor DNA. VolitionRx is shifting its strategic focus from R&D to commercialization, aiming for multiple licensing agreements and eventual widespread adoption of its low-cost, accurate diagnostic tests for cancer and sepsis globally.
At Harvard gala, QT Imaging CEO pushes earlier breast cancer detection
QT Imaging Holdings, Inc. CEO Dr. Raluca Dinu participated in the inaugural Shiftmakers Gala at Harvard University, highlighting the importance of early breast cancer detection. Dinu emphasized that their radiation-free imaging technology addresses the challenge of dense breast tissue, which often makes mammography alone insufficient for many women. The event, supported by Gloria Steinem, focused on women driving change, and QT Imaging's work will be featured in The Shift to further promote awareness.
ResMed Inc. (RMD) stock price, news, quote and history
This article provides comprehensive financial data, news, and historical information for ResMed Inc. (RMD). It includes real-time stock quotes, key statistics, performance over various periods, an overview of the company's operations in medical devices and cloud-based software, and analyst insights. The report also lists financial highlights, profitability metrics, and allows for comparison with similar companies in the Medical Instruments & Supplies industry.
Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North America Leads with 42% Share - Key Players: Becton, Dickinson and Company, Hologic Inc., Boston Scientific Corporation
The global biopsy devices market is projected to reach US$ 6.85 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.15% from US$ 2.68 billion in 2025. This growth is primarily driven by the increasing prevalence of cancer and other chronic diseases, alongside advancements in minimally invasive and image-guided biopsy technologies. North America is expected to maintain its leading position in the market, holding a 42% share, due to its advanced healthcare infrastructure and early adoption of innovative diagnostic tools.
Mammography Machine Market is expected to Hit US$ 4.1 billion by 2033 | Major Companies - GE HealthCare, Hologic, Inc., PLANMED OY, Carestream Health
The global Mammography Machine Market, valued at US$ 2.6 billion in 2024, is projected to reach US$ 4.1 billion by 2033, demonstrating a CAGR of 5.1% from 2025 to 2033. This growth is driven by increasing breast cancer awareness, technological advancements, and a rising demand for early detection solutions. Key players in this market include GE HealthCare, Hologic, Inc., and FUJIFILM Holdings Corporation, with recent developments focusing on 3D tomosynthesis, AI-powered tools, and strategic acquisitions to enhance diagnostic capabilities.
InMode Ltd Stock: Innovative Aesthetic Devices Driving Growth in a Competitive Medical Tech Landscap
InMode Ltd specializes in non-invasive aesthetic medical devices, utilizing radiofrequency and laser technologies for treatments like body contouring and skin rejuvenation. The company's business model involves selling capital equipment and generating recurring revenue from consumables, with a significant global footprint. Despite strong growth and an innovative product lineup, investors should monitor regulatory hurdles, competition, economic downturns, and supply chain disruptions.
Quantum-Si (NASDAQ: QSI) plans 2026 virtual meeting and pay vote
Quantum-Si (NASDAQ: QSI) will hold its fully virtual 2026 annual shareholder meeting on May 15, 2026, at 1:00 p.m. Eastern, where stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving a non-binding advisory say-on-pay for named executive officers. Founder Jonathan M. Rothberg, Ph.D., who beneficially owns all Class B shares, holds approximately 69.33% of the total voting power, effectively controlling the outcome of all proposals. The proxy statement details executive compensation for 2025, outstanding equity awards, and director compensation.
Emerging Sub-Segments Transforming the Medical Device Subscription Market Landscape
The medical device subscription market is projected to reach $24.89 billion by 2030, growing at a CAGR of 22.5%, driven by remote monitoring, AI, and telehealth integration. Key players like Thermo Fisher Scientific and Medtronic are shaping the industry, with innovations like next-generation health wearables fostering personalized wellness management. The market is segmented by device type, subscription model, application, and end-user, including diagnostic, therapeutic, and monitoring devices across various medical fields.
Competitive Analysis: Key Market Leaders and New Entrants in the Lyme Disease Testing Industry
The Lyme disease testing market is projected to reach $16.46 billion by 2030, growing at a CAGR of 9.0%, driven by advancements in diagnostics and increased awareness of tick-borne illnesses. Key trends include AI-assisted tools, home-testing kits, and multi-disease panels. Companies like Roche, Thermo Fisher Scientific, and Quest Diagnostics are leading innovation, with strategic partnerships and technological advancements enhancing early and precise detection methods.
Retirement Systems of Alabama Decreases Stock Holdings in Hologic, Inc. $HOLX
Retirement Systems of Alabama significantly reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 47.7% in the fourth quarter, selling over 332,000 shares and retaining a holding valued at $27.13 million. This move follows Hologic missing its Q4 earnings expectations and several analysts downgrading the stock, resulting in a consensus "Hold" rating with an average price target of $78.42. Institutional investors collectively own 94.73% of the company's stock.
Hologic, Inc. (HOLX) Is Gaining Attention: Key Information to Consider Before Investing
Hologic, Inc. (HOLX) is drawing investor attention, prompting a review of its recent performance, earnings trends, and valuation. Despite a slight increase in share price over the last month, its Zacks Rank #4 (Sell) suggests potential underperformance against the broader market. Investors should consider these fundamental factors alongside its recent financial results and revenue growth outlook.
Hologic, Inc. (HOLX) Is Gaining Attention: Key Information to Consider Before Investing
Hologic, Inc. (HOLX) is drawing investor attention, prompting a review of its recent performance, earnings estimates, and valuation. Despite a slight increase in share price over the past month, the company's Zacks Rank #4 (Sell) suggests potential underperformance in the near future. While earnings and revenue estimates show growth, recent financial results missed consensus expectations.
CIBRA Capital Ltd Purchases Shares of 62,838 Hologic, Inc. $HOLX
CIBRA Capital Ltd initiated a new position in Hologic, Inc. (NASDAQ:HOLX) during Q4, acquiring 62,838 shares valued at approximately $4.68 million, making HOLX its sixth-largest holding. Despite 2.5% year-over-year revenue growth, Hologic missed recent quarterly estimates. Analysts primarily rate the stock as a "Hold" with an average price target of $78.42, while shares trade near their 52-week high.
Nordea Investment Management AB Has $1.74 Million Holdings in Hologic, Inc. $HOLX
Nordea Investment Management AB significantly reduced its stake in Hologic, Inc. by 99.2% in Q4, leaving them with 23,325 shares valued at $1.739 million. This reduction comes as Hologic missed Q4 earnings expectations with EPS of $1.04 against a $1.09 forecast and revenue of $1.05 billion versus $1.07 billion projected. Following these results, several brokers have downgraded the stock, leading to a consensus "Hold" rating and a target price of $78.42.
Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In
Masimo Corp is highlighted as a leading innovator in noninvasive patient monitoring, offering robust growth potential for North American investors. The article details its core business model, technological leadership in pulse oximetry and advanced sensors, and strong market positioning against competitors. It also covers the company's financial health, innovation pipeline, and strategic outlook, while acknowledging risks inherent in the medtech industry.
CIBRA Capital Ltd Acquires Stake in Hologic, Inc.
CIBRA Capital Ltd has acquired 62,838 shares of Hologic, Inc. (NASDAQ:HOLX) stock, valued at approximately $4.68 million, representing a new position for the investment firm. This move highlights CIBRA Capital's confidence in Hologic's market position and growth potential in the women's health sector. The investment firm now holds Hologic as its sixth-largest holding, comprising 8% of its total portfolio.
